Abstract
Currently at least 75% of patients with severe aplastic anaemia can be successfully transplanted using a matched unrelated donor (UD) haematopoietic SCT (HSCT). For children, outcomes are similar to matched sibling donor (MSD) HSCT. This improvement in outcome over time is likely due to improved HLA tissue typing to identify better matched donors, improvements in the conditioning regimen, particularly fludarabine-based regimens, and improved supportive care. Graft rejection occurs in ∼15% of adults, but is less frequent in children. Chronic GVHD remains a concern but may be reduced by using Alemtuzumab instead of ATG. UD HSCT should be considered early after failure to respond to one course of immunosuppressive therapy, but for children who lack a MSD up front matched UD HSCT may be considered.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Maury S, Balere-Appert ML, Chir Z, Boiron JM, Galambrun C, Yakouben K et alFrench Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica 2007; 92: 589–596.
Viollier R, Socié G, Tichelli A, Bacigalupo A, Korthof ET, Marsh J et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant 2008; 41: 45–50.
Kojima S, Matsuyama T, Kato S, Kigasawa H, Kobayashi R, Kikuta A et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 2002; 100: 799–803.
Deeg HJ, Amylon ID, Harris RE, Collins R, Beatty PG, Feig S et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001; 7: 208–215.
Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socié G, Maury S et alSevere Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005; 36: 947–950.
Bacigalupo A, Socie G, Lanino E, Prete A, Locatelli F, Locasciulli A et al. For the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation, (SAA WP-EBMT). Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica 2010; 95: 976–982.
Gupta V, Ball S, Sage D, Ortin M, Freires M, Gordon-Smith E et al. Marrow transplants from matched unrelated donors for aplastic anemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transplant 2005; 35: 467–471.
Siegal D, Xu W, Sutherland R, Kuruvilla J, Lipton JH, Minden M et al. Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies. Bone Marrow Transplant 2008; 42: 51–56.
Gupta V, Ball S, Yi Q, Sage D, McCann S, Lawler M et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biolo Blood Marrow Transplant 2004; 10: 867–876.
Marsh JC, Gupta V, Lim Z, Ho AY, Ireland R, Hayden J et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011; 118: 2351–2357.
Dufour C, Bacigalupo A, Socie G, Tichelli A, Risitano AM, Schrezenmeier H et alEuropean Blood and Marrow Transplant Group, Severe Aplastic Anemia. Rabbit ATG for aplastic anemia treatment: a backward step? Lancet 2011 doi: 10.1016/S0140-6736(11)60817-9.
Bacigalupo A . Back to the OR? Blood 2001; 118: 2386.
Dominietto A, Tedone E, Soracco M, Bruno B, Raiola AM, Van Lint MT et al. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant 2012; 47: 101–106.
Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576–4583.
Takakazu K, Yasuo M, Keitaro M, Koichi K, Hidetoshi I, Hiroh S et al. For The Japan Marrow Donor Program. High-risk HLA alleles mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 2007; 110: 2235–2241.
Crocchiolo R, Zino E, Vago L, Oneto R, Bruno B, Pollichieni S et al. Gruppo Italiano Trapianto di Midollo Osseo, Cellule Staminale Ematopoietiche (CSE) e Terapia Cellulare; Italian Bone Marrow Donor Registry. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood 2009; 114: 1437–1444.
Eapen M, Rademacher JL, Antin JH, Champlin RE, Carreras J, Fay J et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood 2011; 118: 2618–2621.
Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T et al. Rituximab treatment for epstein-barr virus dnaemia after alternative-donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 901–907.
Kennedy-Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA, Gottschalk S et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant 2006; 12: 1277–1284.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
JM had a consultancy with Genzyme 2008/09 and research funding from Genzyme 2010. AB had been on the speakers’ bureau of Genzyme from 2000 to 2011 and has received research funding from Pfizer.
Rights and permissions
About this article
Cite this article
Bacigalupo, A., Marsh, J. Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18–40 years without an HLA-identical sibling and failing immunosuppression. Bone Marrow Transplant 48, 198–200 (2013). https://doi.org/10.1038/bmt.2012.233
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.233
Keywords
This article is cited by
-
Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide
Bone Marrow Transplantation (2020)
-
Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019
Bone Marrow Transplantation (2019)
-
Biomarkers for predicting clinical response to immunosuppressive therapy in aplastic anemia
International Journal of Hematology (2016)
-
Alternative donor transplant of benign primary hematologic disorders
Bone Marrow Transplantation (2015)
-
Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015
Bone Marrow Transplantation (2015)